Counterpoint: The evidence does not support universal screening and treatment in children

Schilling, 2002, Neuroblastoma screening at one year of age, N Engl J Med, 346, 1047, 10.1056/NEJMoa012277 Yamamoto, 1998, Spontaneous regression of localized neuroblastoma detected by mass screening, J Clin Oncol, 16, 1265, 10.1200/JCO.1998.16.4.1265 LeFevre, 2013, PSA screening: good evidence shows little benefit, significant harms, Oncology (Williston Park), 27, 981 Ahn, 2014, Korea's thyroid-cancer “epidemic”–screening and overdiagnosis, N Engl J Med, 371, 1765, 10.1056/NEJMp1409841 Rossouw, 2002, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, JAMA, 288, 321, 10.1001/jama.288.3.321 Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2889, 10.1016/j.jacc.2013.11.002 Gooding, 2015, Application of pediatric and adult guidelines for treatment of lipid levels among US adolescents transitioning to young adulthood, JAMA Pediatr, 169, 569, 10.1001/jamapediatrics.2015.0168 Redberg, 2010, Less is more, Arch Intern Med, 170, 584, 10.1001/archinternmed.2010.48 Schroeder, 2011, Safely doing less: a missing component of the patient safety dialogue, Pediatrics, 128, e1596, 10.1542/peds.2011-2726 2007, Screening for lipid disorders in children: US Preventive Services Task Force recommendation statement, Pediatrics, 120, e215, 10.1542/peds.2006-1812 Friedman, 2006, Sensitivity and specificity of pediatric lipid determinations for adult lipid status: findings from the Princeton Lipid Research Clinics Prevalence Program Follow-up Study, Pediatrics, 118, 165, 10.1542/peds.2005-2968 2011, Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report, Pediatrics, 128, S213 Rifai, 1996, Failure of current guidelines for cholesterol screening in urban African-American adolescents, Pediatrics, 98, 383, 10.1542/peds.98.3.383 Schroeder, 2012, Cholesterol screening and management in children and young adults should start early–NO!, Clin Cardiol, 35, 665, 10.1002/clc.22075 Gillman, 2012, Is universal pediatric lipid screening justified?, JAMA, 307, 259, 10.1001/jama.2011.2012 Bibbins-Domingo, 2007, Adolescent overweight and future adult coronary heart disease, N Engl J Med, 357, 2371, 10.1056/NEJMsa073166 Poirier, 2015, Obesity-it must not remain the neglected risk factor in cardiology, Can J Cardiol, 31, 105, 10.1016/j.cjca.2014.12.017 Doshi, 2009, Short-term change in body mass index in overweight adolescents following cholesterol screening, Arch Pediatr Adolesc Med, 163, 812, 10.1001/archpediatrics.2009.152 Luepker, 1996, Outcomes of a field trial to improve children's dietary patterns and physical activity. The Child and Adolescent Trial for Cardiovascular Health. CATCH collaborative group, JAMA, 275, 768, 10.1001/jama.1996.03530340032026 Nader, 1997, Parent and physician response to children's cholesterol values of 200 mg/dL or greater: the Child and Adolescent Trial for Cardiovascular Health Experiment, Pediatrics, 99, E5, 10.1542/peds.99.5.e5 Lannon, 1992, Parents' behavior and attitudes toward screening children for high serum cholesterol levels, Pediatrics, 89, 1159, 10.1542/peds.89.6.1159 1995, Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. The Dietary Intervention Study in Children (DISC). The Writing Group for the DISC Collaborative Research Group, JAMA, 273, 1429, 10.1001/jama.1995.03520420045036 Jacobs, 1982, Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study, Am J Epidemiol, 116, 878, 10.1093/oxfordjournals.aje.a113490 Schectman, 1996, Variability in cholesterol measurements: comparison of calculated and direct LDL cholesterol determinations, Clin Chem, 42, 732, 10.1093/clinchem/42.5.732 Law, 2006, Statin safety: a systematic review, Am J Cardiol, 97, 52C, 10.1016/j.amjcard.2005.12.010 Law, 2006, Efficacy and safety of cholesterol-lowering treatment, Lancet, 367, 469, 10.1016/S0140-6736(06)68170-1 Mills, 2011, Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials, QJM, 104, 109, 10.1093/qjmed/hcq165 Psaty, 2012, Universal screening and drug treatment of dyslipidemia in children and adolescents, JAMA, 307, 257, 10.1001/jama.2011.1916 Rajpathak, 2009, Statin therapy and risk of developing type 2 diabetes: a meta-analysis, Diabetes Care, 32, 1924, 10.2337/dc09-0738 FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm#sa. Accessed May 19, 2015. Yeboah, 2015, Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA), Am Heart J, 169, 387, 10.1016/j.ahj.2014.12.018 Avis, 2007, A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia, Arterioscler Thromb Vasc Biol, 27, 1803, 10.1161/ATVBAHA.107.145151 Vuorio, 2014, Statins for children with familial hypercholesterolemia, Cochrane database Syst Rev, 7, CD006401 Avis, 2010, Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia, J Am Coll Cardiol, 55, 1121, 10.1016/j.jacc.2009.10.042 Schanberg, 2012, Use of atorvastatin in systemic lupus erythematosus in children and adolescents, Arthritis Rheum, 64, 285, 10.1002/art.30645 Kusters, 2014, Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia, JAMA, 312, 1055, 10.1001/jama.2014.8892 Belay, 2007, The use of statins in pediatrics: knowledge base, limitations, and future directions, Pediatrics, 119, 370, 10.1542/peds.2006-0787 Newman, 2012, Overly aggressive new guidelines for lipid screening in children: evidence of a broken process, Pediatrics, 130, 349, 10.1542/peds.2012-0481 Hamelin, 1998, Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors, Trends Pharmacol Sci, 19, 26, 10.1016/S0165-6147(97)01147-4 Yeganeh, 2014, Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease, Pharmacol Ther, 143, 87, 10.1016/j.pharmthera.2014.02.007 Yamashita, 2014, Statin treatment rescues FGFR3 skeletal dysplasia phenotypes, Nature, 513, 507, 10.1038/nature13775 Liu, 2013, HMG-CoA reductase inhibitors (statins) and bone mineral density: a meta-analysis, Bone, 54, 151, 10.1016/j.bone.2013.01.044 Csoka, 2009, Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology, Med Hypotheses, 73, 770, 10.1016/j.mehy.2008.10.039 Vinci, 2014, Cholesterol testing among children and adolescents during health visits, JAMA, 311, 1804, 10.1001/jama.2014.2410 Dixon, 2014, Implementation of lipid screening guidelines in children by primary pediatric providers, J Pediatr, 164, 572, 10.1016/j.jpeds.2013.10.027 Belamarich, 2006, Drowning in a sea of advice: pediatricians and American Academy of Pediatrics policy statements, Pediatrics, 118, e964, 10.1542/peds.2006-0652 Norlin, 2011, Delivery of well-child care: a look inside the door, Acad Pediatr, 11, 18, 10.1016/j.acap.2010.12.008 Grossman, 2011, The anatomy of a US Preventive Services Task Force Recommendation: lipid screening for children and adolescents, Arch Pediatr Adolesc Med, 165, 205, 10.1001/archpediatrics.2010.299 Ford, 2009, Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States, Circulation, 119, 1108, 10.1161/CIRCULATIONAHA.108.816769 Wilson, 2015, Pediatric dyslipidemia: recommendations for clinical management, South Med J, 108, 7, 10.14423/SMJ.0000000000000219 Watts, 2014, Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation, J Clin Lipidol, 8, 148, 10.1016/j.jacl.2014.01.002 Wilkinson, 2007, Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey, J Rheumatol, 34, 224 Beukelman, 2012, Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry, J Rheumatol, 39, 1867, 10.3899/jrheum.120110